Document is current
Any future updates will be listed below
-
Authors
Elitt, Matthew S. https://orcid.org/0000-0002-7296-164X
Barbar, Lilianne https://orcid.org/0000-0001-9887-4248
Shick, H. Elizabeth
Powers, Berit E.
Maeno-Hikichi, Yuka
Madhavan, Mayur
Allan, Kevin C.
Nawash, Baraa S.
Gevorgyan, Artur S.
Hung, Stevephen
Nevin, Zachary S. https://orcid.org/0000-0003-4987-924X
Olsen, Hannah E.
Hitomi, Midori
Schlatzer, Daniela M.
Zhao, Hien T.
Swayze, Adam
LePage, David F.
Jiang, Weihong
Conlon, Ronald A.
Rigo, Frank
Tesar, Paul J. https://orcid.org/0000-0003-1532-3155
- License Information
-
More Information
Article History
Received: 29 December 2018
Accepted: 24 June 2020
First Online: 1 July 2020
Competing interests
: P.J.T. and M.S.E. are listed as inventors on pending patent claims (PCT/US2017/064870) filed by CWRU covering methods of PLP1 suppression. P.J.T. is a co-founder and consultant for Convelo Therapeutics, which has licensed patents unrelated to the current study from CWRU inventors (P.J.T., M.S.E., Z.S.N. and M.M.). P.J.T. and CWRU retain equity in Convelo Therapeutics. P.J.T. is a consultant and on the Scientific Advisory Board of Cell Line Genetics, which performed karyotyping in this study. P.J.T. is Chair of the Scientific Advisory Board (volunteer position) for the Pelizaeus-Merzbacher Disease Foundation. B.E.P., H.T.Z., A.S. and F.R. are employees of Ionis Pharmaceuticals. No other authors declare competing interests.
